Product Name | Encapsulated Drugs | Type of Liposomes | Indications | Lipid Composition | Particle Size | Status | Reference |
---|---|---|---|---|---|---|---|
nm | |||||||
Alocrest | Vinorelbine | Optisomes | NSCLC and breast cancers, non-Hodgkin’s lymphoma, Hodgkin’s disease | Sphingomyelin and cholesterol | — | Phase I | NCT00364676a (accessed on 14/4/15); Semple et al. (2005); Cattaneo et al. (2010); |
Aroplatin | Analog of cisplatin | MLVs | Advanced pancreatic and colorectal cancer, malignant pleural mesothelioma, advanced solid malignancies | DMPC and DMPG | — | Phase I/II | NCT00043199a (accessed on 14/4/15); Lu et al. (2005); Dragovich et al. (2006) |
ATI-1123 | Docetaxel | Protein stabilized liposomes | NSCLC, gastric, pancreatic cancer, and soft tissue sarcoma | Phospholipids, cholesterol, human serum albumin, and sucrose | 60-80 | Phase I | Mahalingam et al. (2014) |
Brakiva (TLI) | Topotecan | Optisomes | Small cell lung, ovarian cancers and advanced solid tumors | Sphingomyelin and cholesterol | 100 | Phase I | NCT00765973a (accessed on 14/4/15); Tardi et al. (2000) |
NanoVNB | Vinorelbine | PEGylated liposomes | Advanced solid tumors | DSPC, DSPE-PEG2000Da, cholesterol | 98 | Phase I | Yang et al. (2012b); Lin et al. (2013) |
MCC-465 | Doxorubicin | Antibody conjugated PEGylated liposomes | Stomach cancer | DPPC, maleimidated DPPE, PEG, GAH | 143 | Phase I | Hamaguchi et al. (2004); Matsumura et al. (2004) |
SGT-53 | p53 DNA plasmid | Anti-TfR conjugated cationic liposomes | Solid tumors | DOTAP and DOPE | 114 | Phase I | NCT0047061a (accessed on 15/4/15); Xu et al. (2001); Camp et al. (2013); Kim et al. (2015) |
TKM-080301 (TKM-PLK1) | PLK1 siRNA | Cationic PEGylated liposomes | Gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, hepatocellular carcinoma | DSPC, DLin-MC3-DMA, DMG-PEG, and cholesterol | 80-140 | Phase I/II | NCT01262235a (accessed on 15/4/15); Tam et al. (2013); Leung et al. (2014) |
↵a ClinicalTrials.gov identifier
DMPC, 1,2-dimyristoyl phosphatidylcholine; DMPG, 1,2-dimyristoyl phosphatidylglycerol; DPPE, 1,2-dipalmitoyl phosphatidylethanolamine; GAH, human monoclonal antibody; NSCLC, non-small cell lung cancer; DLin-MC3-DMA, heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate; DMG-PEG, polyethylene glycol-dimyristolglycerol; TfR, transferrin receptor